clinical trial · NCT05603052
A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older
EuBiologics Co.,Ltd·phase3·completed·n = 2,852
COVID-19EuCorVac-19ChAdOx1 nCoV-19
brief summary
A phase III, randomized, observer-blind, active-controlled, parallel-group, multi-center study to evaluate immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 in healthy adults aged 18 years and older
started
Jul 11, 2022
primary completion
Jan 15, 2024
completion
Jan 15, 2024
last updated
Jan 7, 2025
official title
A Phase III, Randomized, Observer-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Immunogenicity and Safety of a Preventive COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol